Sanofi-Regeneron Drug Lowers Cholesterol Up to 72% in Study

An experimental drug from Sanofi and Regeneron Pharmaceuticals Inc. lowered patients’ so-called bad cholesterol by as much as 72 percent on top of Lipitor in a company-funded study.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.